Xeris Biopharma Holdings (FRA:2B30) Change In Inventory: €-14.4 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2B30 Xeris Biopharma Holdings Inc FRA:2B30
71 GF Score
Price €7.23
GF Value €4.46
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Xeris Biopharma Holdings Change In Inventory?

Xeris Biopharma Holdings FRA:2B30 -2.24% 71 Change In Inventory is €-14.4 Mil as of Jun. 2026. GuruFocus rates FRA:2B30 with a GF Score™ of 71/100 and a GF Value™ of €4.46 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Xeris Biopharma Holdings's change in inventory for the quarter that ended in Jun. 2026 was €-8.2 Mil. It means Xeris Biopharma Holdings's inventory increased by €8.2 Mil from Mar. 2026 to Jun. 2026 .

Xeris Biopharma Holdings's change in inventory for the fiscal year that ended in Dec. 2025 was €-16.5 Mil. It means Xeris Biopharma Holdings's inventory increased by €16.5 Mil from Dec. 2024 to Dec. 2025 .

Xeris Biopharma Holdings's Total Inventories for the quarter that ended in Jun. 2026 was €70.2 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Xeris Biopharma Holdings's Days Inventory for the quarter that ended in Jun. 2026 was 564.84.

Inventory Turnover measures how fast the company turns over its inventory within a year. Xeris Biopharma Holdings's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.16.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Xeris Biopharma Holdings's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.84.

Xeris Biopharma Holdings  (FRA:2B30) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Xeris Biopharma Holdings's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=67.2295/10.861*365 / 4
=564.84

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Xeris Biopharma Holdings's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=10.861 / 67.2295
=0.16

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Xeris Biopharma Holdings's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=67.2295 / 79.943
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeris Biopharma Holdings Change In Inventory Related Terms

Xeris Biopharma Holdings Change In Inventory Historical Data

* Premium members only.

The historical data trend for Xeris Biopharma Holdings's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeris Biopharma Holdings Change In Inventory Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.57 -7.05 -13.58 -8.39 -16.47

Xeris Biopharma Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.57 -3.48 -3.43 0.74 -8.25
FRA:2B30
71GF Score
Xeris Biopharma Holdings Inc FRA:2B30
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xeris Biopharma Holdings Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of €-14.4 Mil mean?
Xeris Biopharma Holdings (FRA:2B30) has a Change In Inventory of €-14.4 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Xeris Biopharma Holdings and its competitors.
Is Xeris Biopharma Holdings' Change In Inventory too high?
Xeris Biopharma Holdings' current Change In Inventory is €-14.4 Mil. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Change In Inventory compare to HROW and PRGO?
Xeris Biopharma Holdings' Change In Inventory of €-14.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Xeris Biopharma Holdings and its competitors. Xeris Biopharma Holdings's current Change In Inventory is €-14.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (FRA:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.46, compared to a current price of €7.23 — trading 62.1% above its estimated fair value. The current Change In Inventory is €-14.4 Mil. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Xeris Biopharma Holdings (FRA:2B30), the current Change In Inventory is €-14.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xeris Biopharma Holdings (FRA:2B30) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of €7.23 is trading 62.1% above its estimated GF Value™ of €4.46. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for FRA:2B30:

  • Change In Inventory: €-14.4 Mil
  • GF Value™: €4.46 vs. price of €7.23 (62.1% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the FRA:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xeris Biopharma Holdings Business Description

Other Exchanges XERS:USA0A8E:UK2B30:Germany
Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score

Get the complete analysis for FRA:2B30

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.23
Price
€4.46
GF Value